Review



cas no  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress cas no
    Cas No, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cas no/product/MedChemExpress
    Average 93 stars, based on 23 article reviews
    cas no - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    93
    MedChemExpress cas no
    Cas No, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cas no/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    cas no - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    Selleck Chemicals gsk3 β inhibitor ar a014418
    Gsk3 β Inhibitor Ar A014418, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsk3 β inhibitor ar a014418/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    gsk3 β inhibitor ar a014418 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    GlpBio Technology Inc ar-a014418
    Ar A014418, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ar-a014418/product/GlpBio Technology Inc
    Average 90 stars, based on 1 article reviews
    ar-a014418 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    AstraZeneca ltd gsk3 inhibitor ar-a014418
    Gsk3 Inhibitor Ar A014418, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsk3 inhibitor ar-a014418/product/AstraZeneca ltd
    Average 90 stars, based on 1 article reviews
    gsk3 inhibitor ar-a014418 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    93
    Selleck Chemicals gsk 3β inhibitor ar a014418
    The list of 30 compounds identified in the first screening.
    Gsk 3β Inhibitor Ar A014418, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsk 3β inhibitor ar a014418/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    gsk 3β inhibitor ar a014418 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress akt inhibitors mk 2206
    The list of 30 compounds identified in the first screening.
    Akt Inhibitors Mk 2206, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt inhibitors mk 2206/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    akt inhibitors mk 2206 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    Selleck Chemicals gsk3β inhibitors ar a014418
    The list of 30 compounds identified in the first screening.
    Gsk3β Inhibitors Ar A014418, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsk3β inhibitors ar a014418/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    gsk3β inhibitors ar a014418 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    Gilson Inc trf2 inhibitors ar-a014418
    The list of 30 compounds identified in the first screening.
    Trf2 Inhibitors Ar A014418, supplied by Gilson Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trf2 inhibitors ar-a014418/product/Gilson Inc
    Average 90 stars, based on 1 article reviews
    trf2 inhibitors ar-a014418 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    AstraZeneca ltd thiazole compound ar-a014418
    The list of 30 compounds identified in the first screening.
    Thiazole Compound Ar A014418, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/thiazole compound ar-a014418/product/AstraZeneca ltd
    Average 90 stars, based on 1 article reviews
    thiazole compound ar-a014418 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    The list of 30 compounds identified in the first screening.

    Journal: Cancer Medicine

    Article Title: A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma

    doi: 10.1002/cam4.70047

    Figure Lengend Snippet: The list of 30 compounds identified in the first screening.

    Article Snippet: A GSK‐3β inhibitor AR‐A014418 (Cat no. S7435), an IKK inhibitor BMS‐345541 (Cat no. S8044), and a JAK1/JAK2 inhibitor Momelotinib (CYT387, Cat no. S2219) were purchased from Selleck Chemicals.

    Techniques:

    Validation of hit compounds: (A) plate layout of the second screening. The negative and positive control wells, located in either end row of the plate, were prepared in the same manner as in the first screening. KUCaP13_AREluc cells, treated with a 1:3 serial dilution series of eight compounds starting at a final concentration of 10 μM, were plated, adhering to the designated positions shown in the figure. A 10 nM R1881 was added to the wells containing the compound, while it was not added to the wells of the negative control plates. Duplicate plates were tested for each plate; (B)–(D) results of three representative compounds in the second screening; (B) AR‐A014418; (C) BMS‐345541; (D) Cyt387. Data represents mean ± standard deviation (SD). The graph on the left is with R1881, and the graph on the right is without R1881; (E) the scatter plot depicts the results of the second screening. For each compound, a plot was created with the maximum relative luminescence value of the wells with R1881 on the y ‐axis and the relative luminescence value of the wells without R1881 at the concentrations that exhibited the maximum values with R1881 on the x ‐axis. The red line on the y‐axis represents the cutoff value of relative luminescence from wells with R1881 added to the compound, set at 1 + 4 SD (SD = 0.14), or 1.56. The relative luminescence from wells without R1881 added to the compound was expected to fall between the two red lines, 0.8 and 1.2. The region enclosed by the solid red line is the area where true positives are expected. The compounds shown in (B)–(D) were plotted in blue; (F, G) mRNA expression levels of AR (F) and KLK3 (G) normalized by the expression of GAPDH using quantitative qPCR. All cell types were cultured with or without 10 nM R1881. After 24 h, LNCaP cells, KUCaP13 cells, and KUCaP13_AREluc_AR cells were treated with 0.1% DMSO and cultured for a total of 72 h. In addition, KUCaP13_AREluc cells were treated with 0.1% DMSO, or 10 μM of AR‐A014418, BMS‐345541, and CYT387 after 24 h, and cultured for a total of 72 h. Data represent mean ± standard error of the mean.

    Journal: Cancer Medicine

    Article Title: A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma

    doi: 10.1002/cam4.70047

    Figure Lengend Snippet: Validation of hit compounds: (A) plate layout of the second screening. The negative and positive control wells, located in either end row of the plate, were prepared in the same manner as in the first screening. KUCaP13_AREluc cells, treated with a 1:3 serial dilution series of eight compounds starting at a final concentration of 10 μM, were plated, adhering to the designated positions shown in the figure. A 10 nM R1881 was added to the wells containing the compound, while it was not added to the wells of the negative control plates. Duplicate plates were tested for each plate; (B)–(D) results of three representative compounds in the second screening; (B) AR‐A014418; (C) BMS‐345541; (D) Cyt387. Data represents mean ± standard deviation (SD). The graph on the left is with R1881, and the graph on the right is without R1881; (E) the scatter plot depicts the results of the second screening. For each compound, a plot was created with the maximum relative luminescence value of the wells with R1881 on the y ‐axis and the relative luminescence value of the wells without R1881 at the concentrations that exhibited the maximum values with R1881 on the x ‐axis. The red line on the y‐axis represents the cutoff value of relative luminescence from wells with R1881 added to the compound, set at 1 + 4 SD (SD = 0.14), or 1.56. The relative luminescence from wells without R1881 added to the compound was expected to fall between the two red lines, 0.8 and 1.2. The region enclosed by the solid red line is the area where true positives are expected. The compounds shown in (B)–(D) were plotted in blue; (F, G) mRNA expression levels of AR (F) and KLK3 (G) normalized by the expression of GAPDH using quantitative qPCR. All cell types were cultured with or without 10 nM R1881. After 24 h, LNCaP cells, KUCaP13 cells, and KUCaP13_AREluc_AR cells were treated with 0.1% DMSO and cultured for a total of 72 h. In addition, KUCaP13_AREluc cells were treated with 0.1% DMSO, or 10 μM of AR‐A014418, BMS‐345541, and CYT387 after 24 h, and cultured for a total of 72 h. Data represent mean ± standard error of the mean.

    Article Snippet: A GSK‐3β inhibitor AR‐A014418 (Cat no. S7435), an IKK inhibitor BMS‐345541 (Cat no. S8044), and a JAK1/JAK2 inhibitor Momelotinib (CYT387, Cat no. S2219) were purchased from Selleck Chemicals.

    Techniques: Positive Control, Serial Dilution, Concentration Assay, Negative Control, Standard Deviation, Expressing, Cell Culture